KR920703563A - 6-(하이드로나프틸-1-에틸)-4-히드록시-3,4,5,6-테트라하이드로-2h-피란-2온과 이의 해당 히드록시산 - Google Patents
6-(하이드로나프틸-1-에틸)-4-히드록시-3,4,5,6-테트라하이드로-2h-피란-2온과 이의 해당 히드록시산Info
- Publication number
- KR920703563A KR920703563A KR1019920700007A KR920700007A KR920703563A KR 920703563 A KR920703563 A KR 920703563A KR 1019920700007 A KR1019920700007 A KR 1019920700007A KR 920700007 A KR920700007 A KR 920700007A KR 920703563 A KR920703563 A KR 920703563A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- enyl
- compound
- oxobutyl
- octahydro
- Prior art date
Links
- 150000001261 hydroxy acids Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- -1 1, 2, 4a, 5, 6, 7, 8, 8a-octahydro-2-methyl-8-[(2 "-Methyl-1" -oxobutyl) oxy] -6-[(E) -but-1-enyl] -1-naphthalenyl Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000000203 mixture Chemical class 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 229920006317 cationic polymer Polymers 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
내용 없음
Description
6-(하이드로나프틸-1-에틸)-4-히드록시-3,4,5,6-테트라하이드로-2H-피란-2온과 이의 해당 히드록시산
[도면의 간단한 설명]
제1도는 일반식(I)의 화합물과 분족(IIa), (IIb), (IId)와의 상호전환과 일반식(I)의 화합물과 일반식(IV)과의 상호전환을 나타낸 반응식(I)을 도시한 것이다.
제2도는 일반식(VII)의 화합물로부터 차례로 제조할 수 있는 일반식(XIV)의 화합물로부터 분족(IIa)와 (IIe)의 화합물의 정제방법을 나타낸 반응식(II)를 도시한 것이다.
제3도는 일반식(XV)의 화합물 때와 다른 일반식(XIV)의 화합물의 정제방법을 나타낸, 반응식(III)을 도시한 것이다.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (15)
- 다음 일반식(I)과 (II)로 표시되는 어느 한 화합물.상기식에서, R1은 C1-8알킬, C3-8시클로알킬, C3-8시클로알킬(C1-8)알킬, C2-8알켄일, 또는 페닐기로 치환된 C1-6알킬을 나타내며; R2는 C1-8알킬, C2-8알켄일, C2-8알킬기 또는 치환 페닐기로 치환된 C1-5알킬, C2-5알켄일, 또는 C2-5알킨일기를 나타내며; R3는 수소원자 또는 치환기 R4또는 M을 나타내며; R4는 C1-5알킬기 또는 치환페닐, 디메틸아미노와 아세틸아미노에서 선택한기로 치환된 C1-5알킬기를 나타내며; R5는 R2가 메틸일때 R5가 메틸이 아닌 것을 제외하고 수소원자 또는 메틸이나 에틸기를 나타내며, M은 제약적으로 수용할 수 있는 염을 형성할 수 있는 양이온을 나타내며; Q는 C=O 또는 CHOH를 나타내며; a, b, c와 d각각은 a와c가 이중결합일때, b가 단일 결합인 것을 제외하고 독립적으로 단일 또는 이중결합을 나타낸다.
- 제l항에 있어서, 독립적으로 또는 조합하여 하나 또는 그 이상의 다음 치환기를 가짐을 특징으로 하는 화합물.R1은 C4-6분지쇄 알킬을 나타내고; R2는 C2-5알켄일 또는 치환페닐로 치환된 C2-5알켄일을 나타내며; R3는 R4이고; R4는 C1-5알킬, 바람직하기로는 메틸 또는 에틸을 나타내며, Q는 CHOH를 나타내고; b와 d는 둘다 단일결합이고, a와 c중 하나 또는 둘다 이중결합을 나타낸다.
- 제1항에 있어서, R1이 C4-6분지쇄 알킬기를 나타내고; R2가 C2-6알켄일기를 나타내고; a와 c가 각각이 독립적으로 단일 또는 이중결합을 나타내고 b와 d각각은 단일결합을 나타냄을 특징으로 하는 화합물.
- (A)(1S, 2S, 4aR, 6S, 8S, 8aS, 4'R, 6'R, 2"S)-6'-{2-(1,2,4,5,6,7,8,8a-옥타하이드로-2-메틸-8-[(2"-메틸-1"-옥소부틸)옥시]-6-[(Z)-프로프-1-엔일]-1-나트탈렌일-에틸-테트라하이드로-4'-히드록시-2H-피란-2'-온; (B)나트륨(1S, 2S, 4aR, 6S, 8S, 8aS, 3'R, 5'R, 2"S)-7'-(1, 2, 4a, 5, 6, 7, 8, 8a-옥타하이드로-2-메틸-8-[(2"-메틸-1"-옥소부틸)옥시]-6-[(Z)-프로프-1-앤일]-1-나프탈렌일)-3'-5'-디히드록시헵타노에이트 (C)(1S, 2S, 4aR, 6S, 8S, 8aS, 4'R, 6'R)-6'-{2-(1, 2, 4a, 5, 6, 7, 8, 8a-옥타하이드로-2-메틸-8-[(2"-디메틸-1"-옥소부틸)옥시]-6-[(Z)-프로프-1-앤일]-1-나프탈렌일)에틸}-테트라하이드로-4'-히드록시-2H-피란-2'-온; (D)(1S, 2S, 4aR, 6S, 8S, 8aS, 4'R, 6'R)-6'-{2-(1, 2, 4a, 5, 6, 7, 8, 8a-옥타하이드로-2-메틸-8-[(2"-메틸-1"-옥소부틸)옥시]-6-[(E)-부트-1-엔일]-1-나프탈렌일)에틸}-테트라하이드로-4'-히드록시-2H-피란-2'-온; (E)(1S, 2S, 4aR, 6S, 8S, 8aS, 4'R, 6'R, 2"S)-6'-{2-(1, 2, 4a, 5, 6, 7, 8, 8a-옥타하이드로-2-메틸-8-[(2"-메틸-1"-옥소부틸)옥시]-6-[(E)-헥스-1-엔일]-1-나프탈렌일)에틸}테트라하이드로-4'-히드록시-2H-피란-2'-온; 또는 (F) (1S, 2S, 4aR, 6S, 8S, 8aS, 4'R, 6'R, 2"S)-6'-{2-(1, 2, 4a, 5, 6, 7, 8, 8a-옥타하이드로-2-메틸-8-[(2"-디메틸-1"-옥소부틸)옥시]-6-[(E)-헥스-1-엔일]-1-나프탈렌일)에틸}-테트라하이드로-4'-히드록시-2H-피란-2'-온.
- 제3항에 있어서, R1이 C4-5분지쇄 알킬기기를 나타내고; R2가 (E)-프로프-1-엔일을 나타내고; R5가 메틸을 나타냄을 특징으로하는 화합물.
- (G) (1S, 2S, 4aR, 6S, 8S, 8aS, 4'R, 6'R, 2"S)-6'-{2-(1, 2, 4a, 5, 6, 7, 8, 8a-옥타하이드로-2-메틸-8-[(2"-메틸-1"-옥소부틸)옥시]-6-[(E)-프로프-1-엔일]-1-나프탈렌일)에틸}-테트라하이드로-4'-히드록시-2H-피란-2'-온; (H)메틸(1S, 2S, 4aR, 6S, 8S, 8aS, 3'R, 5'R, 2"S)-7'-(1, 2, 4a, 5, 6, 7, 8, 8a-옥타하이드로-2-메틸-8-[(2"-메틸-1"-옥소부틸)옥시]-6-[(E)-프로프-1-엔일]-1-나프탈렌일)-3'-5'-디히드록시헵타노에이트, (J)메틸(1S, 2S, 4aR, 6S, 8S, 8aS, 3'R, 2"S)-7'-(1, 2, 4a, 5, 6, 7, 8, 8a-옥타하이드로-2-메틸-8-[(2"-디메틸-1"-옥소부틸)옥시]-6-[(E)-프로프-1-엔일]-1-나프탈렌일)-3'-히드록시-5'-옥소헵타노에이트; (K)(1S, 2S, 4aR, 6S, 8S, 8aS, 4'R, 6'R)-6'-{2-(1, 2, 4a, 5, 6, 7, 8, 8a-옥타하이드로-2-메틸-8-[(2"-메틸-1"-옥소부틸)옥시]-6-[(E)-프로프-1-엔일]-1-나프탈렌일)에틸}-테트라하이드로-4'-히드록시-2H-피란-2'-온; (L) 메틸(1S, 2S, 4aR, 6S, 8S, 8aS, 3'R, 5'R)-7'-(1, 2, 4a, 5, 6, 7, 8, 8a-옥타하이드로-2-메틸-8-[(2"-메틸-1"-옥소부틸)옥시]-6-[(E)-프로프-1-엔일]-1-나프탈렌일)-3'-5'-디히드록시헵타노에이트; (M)메틸(1S, 2S, 4aR, 6S, 8S, 8aS, 3'R)-7'-(1, 2, 4a, 5, 6, 7, 8, 8a-옥타하이드로-2-메틸-8-[(2"-디메틸-1"-옥소부틸)옥시]-6-[(E)-프로프-1-엔일]-1-나프탈렌일)-3'-히드록시-5'-옥소헵타노에이트; 또는 (N)나트륨(1S, 2S, 4aR, 6S, 8S, 8aS, 3'R, 5'R)-7'-(1, 2, 4a, 5, 6, 7, 8, 8a-옥타하이드로-2-메틸-8-[(2"-디메틸-1"-옥소부틸)옥시]-6-[(E)-프로프-1-엔일]-1-나프탈렌일)-3',5'-디히드록시헵타노에이트.
- 제1항에 있어서, R1이 C4-6분지쇄 알킬기를 나타내고, R2가 임의로 치환된 페닐기에 의하여 치환된 C2-5알켄일기를 나타내고 a와 c각각은 독립적으로 단일 또는 이중결합을 나타내고; b와 d각각은 단일결합을 나타냄을 특징으로하는 화합물.
- 제7항에 있어서, R1이 분지쇄C4알킬기를 나타내고; R2가 프로프-1-엔일을 나타내고; R3은 메틸 또는 에틸을 나타내고, R5가 메틸을 나타내고, Q가 CHOH기를 나타냄을 특징으로 하는 화합물.
- (P) (1S, 2S, 4aR, 6S, 8S, 8aS, 4'R, 6'R, 2"S)-6'-{2-(1, 2, 4a, 5, 6, 7, 8,8a-옥타하이드로-2-메틸-8-[(2"-메틸-1"-옥소부틸)옥시]-6-[3-페닐-(E)-프로프-1-엔일]-1-나트탈렌일)-에틸}-테트라 하이드로-4'-히드록시-2H-피란-2'-온; 또는 (Q) (1S, 2S, 4aR, 6S, 8S, 8aS, 4'R, 6'R, 2"S)-6'-{2-(1, 2, 4a, 5, 6, 7, 8, 8a-옥타하이드로-2-메틸-8-[(2"-디메틸-1"-옥소부틸)옥시]-6-[3-페닐-(E)-프로프-1-엔일]-1-나프탈렌일)-에틸}-테드라하이드로-4'-히드록시-2H-피란-2'-온.
- 의약으로 사용하는 제1항 내지 제9항중 어느 한 항에 언급된 화합물.
- 항과콜레스테롤 혈증제의 제조에 사용하는 제1항 내지 제9항중 어느 한 항에 언급된 화합물의 용도.
- 제1항 내지 제9항중 어느 한 항에 있어서, 언급된 화합물, 또는 이러한 화합물의 혼합물과 제약적으로 수용할 수 있는 담체로 이루어짐을 특징으로하는 제약적 조성물.
- 제12항에 있어서, 위장관에서 비-재흡수성 형태로 빌산을 결합할 수 있는 제약적으로 수용할 수 있는 비-독성 양이온 중합체로 이루어짐을 특징으로 하는 조성물.
- (a) 반응식(II)에 표시된 바와 같이 일반식(XIV)의 화합물을 탈보호하고 임의로 환원하여 일반식(IIa)의 화합물을 형성시키고; (b)R5가 메틸일때, 일반식 LXXIII의 화합물을 탈보호하여 일반식(I)의 화합물을 형성시키고; (c)임의적으로 단계(a)또는 (b)후에, 일반식(I)또는 (IIa)의 화합물을 직접 또는 간접적으로 일반식(I)또는(II)의 다른 화합물로 변환시키는 단계로 이루어짐을 특징으로 하는 제1항에 명시된 일반식(I)과 (II)중 어느 한 화합물의 제조방법.
- 일반식(IV),(X IV) 또는 (LXXIII)의 화합물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8915280.5 | 1989-07-04 | ||
GB898915280A GB8915280D0 (en) | 1989-07-04 | 1989-07-04 | Compounds |
PCT/GB1990/001030 WO1991000280A1 (en) | 1989-07-04 | 1990-07-04 | 6-(hydronaphtyl-1-ethyl)-4-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-ones and the corresponding hydroxy acids |
Publications (1)
Publication Number | Publication Date |
---|---|
KR920703563A true KR920703563A (ko) | 1992-12-18 |
Family
ID=10659493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920700007A KR920703563A (ko) | 1989-07-04 | 1990-07-04 | 6-(하이드로나프틸-1-에틸)-4-히드록시-3,4,5,6-테트라하이드로-2h-피란-2온과 이의 해당 히드록시산 |
Country Status (14)
Country | Link |
---|---|
US (1) | US5308864A (ko) |
EP (1) | EP0480986A1 (ko) |
JP (1) | JPH04506523A (ko) |
KR (1) | KR920703563A (ko) |
AU (1) | AU631909B2 (ko) |
CA (1) | CA2060212A1 (ko) |
FI (1) | FI920036A0 (ko) |
GB (1) | GB8915280D0 (ko) |
HU (1) | HUT62254A (ko) |
IE (1) | IE902417A1 (ko) |
NO (1) | NO920057L (ko) |
NZ (1) | NZ234369A (ko) |
PT (1) | PT94584A (ko) |
WO (1) | WO1991000280A1 (ko) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9111192D0 (en) * | 1991-05-23 | 1991-07-17 | British Bio Technology | Synthetic process |
GB9115773D0 (en) * | 1991-07-22 | 1991-09-04 | British Bio Technology | Synthetic process |
GB9126144D0 (en) * | 1991-12-10 | 1992-02-12 | British Bio Technology | Compounds |
GB9208790D0 (en) * | 1992-04-23 | 1992-06-10 | British Bio Technology | Compounds |
NZ250609A (en) * | 1992-12-28 | 1995-07-26 | Sankyo Co | Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments |
US5990172A (en) * | 1996-02-28 | 1999-11-23 | Innapharma, Inc. | Peptidomimetics for the treatment of HIV infection |
US5925672A (en) * | 1996-12-06 | 1999-07-20 | Neurosciences Research Foundation, Inc. | Methods of treating mental diseases, inflammation and pain |
ES2234323T3 (es) * | 1998-12-10 | 2005-06-16 | Kaneka Corporation | Procedimiento para producir un precursor de simvastatina. |
US20050113445A1 (en) * | 2003-02-20 | 2005-05-26 | Daniele Piomelli | Methods of treating mental diseases, inflammation and pain |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4293496A (en) * | 1980-02-04 | 1981-10-06 | Merck & Co., Inc. | 6(R)-[2-(8-Hydroxy-2,6-dimethylpolyhydronaphthyl-1)-ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-ones |
AU548996B2 (en) * | 1980-02-04 | 1986-01-09 | Merck & Co., Inc. | Tetrahydro-2h-pyran-2-one derivatives |
CA1327360C (en) * | 1983-11-14 | 1994-03-01 | William F. Hoffman | Oxo-analogs of mevinolin-like antihypercholesterolemic agents |
US4668699A (en) * | 1985-08-05 | 1987-05-26 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
US4661483A (en) * | 1986-05-05 | 1987-04-28 | Merck & Co., Inc. | Antihypercholesterolemic lactone compounds, compositions and use |
US4771071A (en) * | 1986-05-05 | 1988-09-13 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
PT85109A (en) * | 1986-06-23 | 1987-07-01 | Merck & Co Inc | Process for the preparation of hydroxy-tetrahydropyranone derivatives or corresponding ring opened dihydroxy acids which are hmg-coa reductase inhibitors |
-
1989
- 1989-07-04 GB GB898915280A patent/GB8915280D0/en active Pending
-
1990
- 1990-07-04 KR KR1019920700007A patent/KR920703563A/ko not_active Application Discontinuation
- 1990-07-04 HU HU9222A patent/HUT62254A/hu unknown
- 1990-07-04 IE IE241790A patent/IE902417A1/en unknown
- 1990-07-04 NZ NZ234369A patent/NZ234369A/xx unknown
- 1990-07-04 US US07/773,657 patent/US5308864A/en not_active Expired - Fee Related
- 1990-07-04 JP JP2510204A patent/JPH04506523A/ja active Pending
- 1990-07-04 AU AU60322/90A patent/AU631909B2/en not_active Ceased
- 1990-07-04 EP EP90910793A patent/EP0480986A1/en not_active Withdrawn
- 1990-07-04 WO PCT/GB1990/001030 patent/WO1991000280A1/en not_active Application Discontinuation
- 1990-07-04 PT PT94584A patent/PT94584A/pt not_active Application Discontinuation
- 1990-07-04 CA CA002060212A patent/CA2060212A1/en not_active Abandoned
-
1992
- 1992-01-03 FI FI920036A patent/FI920036A0/fi not_active Application Discontinuation
- 1992-01-03 NO NO92920057A patent/NO920057L/no unknown
Also Published As
Publication number | Publication date |
---|---|
PT94584A (pt) | 1991-04-18 |
US5308864A (en) | 1994-05-03 |
NZ234369A (en) | 1991-10-25 |
JPH04506523A (ja) | 1992-11-12 |
NO920057D0 (no) | 1992-01-03 |
HU9200022D0 (en) | 1992-07-28 |
HUT62254A (en) | 1993-04-28 |
FI920036A0 (fi) | 1992-01-03 |
AU631909B2 (en) | 1992-12-10 |
NO920057L (no) | 1992-03-03 |
EP0480986A1 (en) | 1992-04-22 |
CA2060212A1 (en) | 1991-01-05 |
GB8915280D0 (en) | 1989-08-23 |
AU6032290A (en) | 1991-01-17 |
WO1991000280A1 (en) | 1991-01-10 |
IE902417A1 (en) | 1991-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL930009I1 (nl) | 6(R)-[2-(8'-Acyloxy-2'-methyl-6'-methyl(of waterstof)-polyhydronaftyl-1')-ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-onen,de hydroxyzuurvorm van deze pyranonen,de farmaceutisch aanvaardbare zouten van genoemde hydroxyzuren,en de door kleine alkyl-en fenyl-, dimethylamino-of acetylaminoresten oxyzuur, werwijzen ter bereiding ervan en een farmaceutisch antihypercholosterolemisch preparaat, dat dit bevat | |
KR920703563A (ko) | 6-(하이드로나프틸-1-에틸)-4-히드록시-3,4,5,6-테트라하이드로-2h-피란-2온과 이의 해당 히드록시산 | |
KR890012970A (ko) | 테트라히드로 이소퀴놀린 유도체 | |
BE2014C034I2 (en) | Derivatives of 3-(2-oxo- 1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems | |
KR890011876A (ko) | 신규한 이소퀴놀린 유도체 그의 제조방법 및 그를 함유하는 제약학적 조성물 | |
EP1172107A4 (en) | MEDICINES CONTAINING SULFOPYRANOSYLACYLGLYCEROL DERIVATIVES | |
IL96636A0 (en) | Piperidine derivatives and pharmaceutical compositions containing them | |
KR900018048A (ko) | 환 치환된 2-아미노-1,2,3,4-테트라하이드로나프탈렌 | |
AU560980B2 (en) | New vitro alphatic compounds | |
IE36116B1 (en) | Furylmethyl morphinane derivatives and pharmaceutical compositions containing them | |
KR940003953A (ko) | 1. 4-벤조디옥산 유도체 | |
SE8505716D0 (sv) | Novel compounds and conjugates thereof | |
AU656674B2 (en) | New thiochroman compounds, processes for the preparation thereof, and pharmaceutical compositions containing them | |
KR910004627A (ko) | 피리도[3,4-b][1,4]벤즈옥사제핀, 이의 제조방법 및 약제로서의 이의 용도 | |
ATE445589T1 (de) | Neue retinoidderivate und eine pharmazeutische anti-krebs-zusammensetzung, die diese verbindungen enthält | |
KR880003914A (ko) | 5-메틸-10,11-디하이드로-5H-디벤조-[a,d] 사이클로헵텐-5,10-이민의 유도체 | |
ATE11912T1 (de) | ((indol-3-yl)-3-amino-2-propionyloxy)-2essigs|urederivate, verfahren zu ihrer herstellung und heilmittel, die sie enthalten. | |
KR840007729A (ko) | 2H-[1] 벤즈옥세피노 [5,4-b]-1,4-옥사진 유도체의 제조방법 | |
KR890016026A (ko) | 살리실산 유도체 | |
AU677146B2 (en) | Agent acting on the central nervous system, process for its preparation and pharmaceutical compositions containing it | |
KR910006280A (ko) | 이미다졸 유도체, 제약학적으로 허용가능한 이들의 산 부가염 및 이들의 제조 방법 | |
DE3481707D1 (de) | 7-alpha-substituierte 3-oxo-17alpha-pregn-4-en-21.17-carbolactone, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate. | |
JPS6468367A (en) | Novel bicyclic ethers or lactones | |
KR890003758A (ko) | 피롤로[2,1-a]이소피롤린 유도체, 그들의 제조방법, 그들을 함유하는 조성물 및 그들의 이용 | |
ID18021A (id) | Pembuatan aldehid asam gamma-halotiglik |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |